Skip to main content

Advertisement

SpringerLink
Log in

Role of quantitative and qualitative characteristics of free circulating DNA in the management of patients with non-small cell lung cancer

  • Review
  • Published:
Cellular Oncology Aims and scope Submit manuscript

Abstract

Background

The release of DNA into peripheral blood is a common event in cancer patients, occurring as a consequence of necrotic and apoptotic processes typical of tumor cells. However, free circulating DNA (fcDNA) is also present in patients with benign diseases and in healthy individuals. Both quantitative and qualitative aspects of fcDNA have been studied as potential biomarkers in a number of tumor types. In particular, quantitative analysis of fcDNA has been shown to play an important role in the diagnosis of non-small cell lung cancer (NSCLC), because of its ability to discriminate between healthy subjects and individuals with NSCLC. Additionally, fcDNA in cancer patients derives predominantly from tumor tissue and, as such, it can be used for the molecular characterization of the primary tumor. Targeted therapies in NSCLC have, in recent years, produced promising results, highlighting the importance of molecular profiling of the primary cancer lesions. Considering that little or no tumor material is available for at least some of the patients, the possibility of using fcDNA for molecular analysis becomes increasingly important. In the present review we evaluated several quantitative and qualitative aspects of fcDNA that could be instrumental for the differential diagnosis of lung disease.

Conclusions

There is ample evidence in the literature to support the possible use of peripheral blood-derived fcDNA in the early diagnosis and molecular characterization of lung cancer. This non-invasive method may also turn out to be valuable in monitoring drug response and in identifying induced mechanisms of drug resistance. Before it can be implemented in routine clinical practice, however, additional efforts are needed to standardize the methodology.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. R. Swaminathan, A.N. Butt, Circulating nucleic acids in plasma and serum: recent developments. Ann. N. Y. Acad. Sci. 1075, 1–9 (2006)

    PubMed  CAS  Google Scholar 

  2. K. Jung, M. Fleischhacker, A. Rabien, Cell-free DNA in the blood as a solid tumor biomarker- a critical appraisal of the literatue. Clin. Chim. Acta 411(21–22), 1611–1624 (2010)

    PubMed  CAS  Google Scholar 

  3. A. Ziegler, U. Zangemeister-Wittke, R.A. Stahel, Circulating DNA: a new diagnostic gold mine? Cancer Treat. Rev. 28(5), 255–271 (2002)

    PubMed  CAS  Google Scholar 

  4. N. Suzuki, A. Kamataki, J. Yamaki, Y. Homma, Characterization of circulating DNA in healthy human plasma. Clin. Chim. Acta 387(1–2), 55–58 (2008)

    PubMed  CAS  Google Scholar 

  5. M. Stroun, P. Maurice, V. Vasioukhin, J. Lyautey, C. Lederrey, F. Lefort, A. Rossier, X.Q. Chen, P. Anker, The origin and mechanism of circulating DNA. Ann. N. Y. Acad. Sci. 906, 161–168 (2000)

    PubMed  CAS  Google Scholar 

  6. M. Stroun, J. Lyautey, C. Lederrey, A. Olson-Sand, P. Anker, About the possible origin and mechanism of circulating DNA apoptosis and active DNA release. Clin. Chim. Acta 313(1–2), 139–142 (2001)

    PubMed  CAS  Google Scholar 

  7. C.N. Li, H.L. Hsu, T.L. Wu, K.C. Tsao, C.F. Sun, J.T. Wu, Cell-free DNA is released from tumor cells upon cell death: a study of tissue cultures of tumor cell lines. J. Clin. Lab. Anal. 17(4), 103–107 (2003)

    PubMed  CAS  Google Scholar 

  8. D.C. García-Olmo, J. Samos, M.G. Picazo, A.I. Asensio, I. Toboso, D. García-Olmo, Release of cell-free DNA into the bloodstream leads to high levels of non-tumor plasma DNA during tumor progression in rats. Cancer Lett. 272(1), 133–140 (2008)

    PubMed  Google Scholar 

  9. H. Fiegl, S. Millinger, E. Mueller-Holzner, C. Marth, C. Ensinger, A. Berger, H. Klocker, G. Goebel, M. Widschwendter, Circulating tumor-specific DNA: a marker for monitoring efficacy of adjuvant therapy in cancer patients. Cancer Res. 65(4), 1141–1145 (2005)

    PubMed  CAS  Google Scholar 

  10. A. Altimari, A.D. Grigioni, E. Benedettini, E. Gabusi, R. Schiavina, A. Martinelli, A.M. Morselli-Labate, G. Martorana, W.F. Grigioni, M. Fiorentino, Diagnostic role of circulating free plasma DNA detection in patients with localized prostate cancer. Am. J. Clin. Pathol. 129(5), 756–762 (2008)

    PubMed  CAS  Google Scholar 

  11. P.J. Bastian, G.S. Palapattu, S. Yegnasubramanian, X. Lin, C.G. Rogers, L.A. Mangold, B. Trock, M. Eisenberger, A.W. Partin, W.G. Nelson, Prognostic value of preoperative serum cell-free circulating DNA in men with prostate cancer undergoing radical prostatectomy. Clin. Cancer Res. 13(18 Pt 1), 5361–5367 (2007)

    PubMed  CAS  Google Scholar 

  12. E. Papadopoulou, E. Davilas, V. Sotiriou, E. Georgakopoulos, S. Georgakopoulou, A. Koliopanos, F. Aggelakis, K. Dardoufas, N.J. Agnanti, I. Karydas, G. Nasioulas, Cell-free DNA and RNA in plasma as a new molecular marker for prostate and breast cancer. Ann. N. Y. Acad. Sci. 1075, 235–243 (2006)

    PubMed  CAS  Google Scholar 

  13. K. Jung, C. Stephan, M. Lewandowski, S. Klotzek, M. Jung, G. Kristiansen, M. Lein, S.A. Loening, D. Schnorr, Increased cell-free DNA in plasma of patients with metastatic spread in prostate cancer. Cancer Lett. 205(2), 173–180 (2004)

    PubMed  CAS  Google Scholar 

  14. X.Y. Zhong, A. Ladewig, S. Schmid, E. Wight, S. Hahn, W. Holzgreve, Elevated level of cell-free plasma DNA is associated with breast cancer. Arch. Gynecol. Obstet. 276(4), 327–331 (2007)

    PubMed  CAS  Google Scholar 

  15. C. Kohler, R. Radpour, Z. Barekati, R. Asadollahi, J. Bitzer, E. Wight, N. Bürki, C. Diesch, W. Holzgreve, X.Y. Zhong, Levels of plasma circulating cell free nuclear and mitochondrial DNA as potential biomarkers for breast tumors. Mol. Cancer 8, 105 (2009)

    PubMed  Google Scholar 

  16. H. Schwarzenbach, V. Müller, N. Stahmann, K. Pantel, Detection and characterization of circulating microsatellite-DNA in blood of patients with breast cancer. Ann. N. Y. Acad. Sci. 1022, 25–32 (2004)

    PubMed  CAS  Google Scholar 

  17. G. Sozzi, D. Conte, M. Leon, R. Ciricione, L. Roz, C. Ratcliffe, E. Roz, N. Cirenei, M. Bellomi, G. Pelosi, M.A. Pierotti, U. Pastorino, Quantification of free circulating DNA as a diagnostic marker in lung cancer. J. Clin. Oncol. 21(21), 3902–3908 (2003)

    PubMed  CAS  Google Scholar 

  18. P. Ulivi, L. Mercatali, W. Zoli, D. Dell’amore, V. Poletti, G.L. Casoni, E. Scarpi, E. Flamini, D. Amadori, R. Silvestrini, Serum free DNA and COX-2 mRNA expression in peripheral blood for lung cancer detection. Thorax 63(9), 843–844 (2008)

    PubMed  CAS  Google Scholar 

  19. E. Flamini, L. Mercatali, O. Nanni, D. Calistri, R. Nunziatini, W. Zoli, P. Rosetti, N. Gardini, A. Lattuneddu, G.M. Verdecchia, D. Amadori, Free DNA and carcinoembryonic antigen serum levels: an important combination for diagnosis of colorectal cancer. Clin. Cancer Res. 12(23), 6985–6988 (2006)

    PubMed  CAS  Google Scholar 

  20. R. Catarino, M.M. Ferreira, H. Rodrigues, A. Coelho, A. Nogal, A. Sousa, R. Medeiros, Quantification of free circulating tumor DNA as a diagnostic marker for breast cancer. DNA Cell Biol. 27(8), 415–421 (2008)

    PubMed  CAS  Google Scholar 

  21. C.P. Chang, R.H. Chia, T.L. Wu, K.C. Tsao, C.F. Sun, J.T. Wu, Elevated cell-free serum DNA detected in patients with myocardial infarction. Clin. Chim. Acta 327(1–2), 95–101 (2003)

    PubMed  CAS  Google Scholar 

  22. G.J. Fournié, F. Martres, J.P. Pourrat, C. Alary, M. Rumeau, Plasma DNA as cell death marker in elderly patients. Gerontology 39(4), 215–221 (1993)

    PubMed  Google Scholar 

  23. T.H. Rainer, N.Y. Lam, Circulating nucleic acids and critical illness. Ann. N. Y. Acad. Sci. 1075, 271–277 (2006)

    PubMed  CAS  Google Scholar 

  24. J.M. Silva, J. Silva, A. Sanchez, J.M. Garcia, G. Dominguez, M. Provencio, L. Sanfrutos, E. Jareño, A. Colas, P. España, F. Bonilla, Tumor DNA in plasma at diagnosis of breast cancer patients is a valuable predictor of disease-free survival. Clin. Cancer Res. 8(12), 3761–3766 (2002)

    PubMed  CAS  Google Scholar 

  25. N. Ren, Q.H. Ye, L.X. Qin, B.H. Zhang, Y.K. Liu, Z.Y. Tang, Circulating DNA level is negatively associated with the long-term survival of hepatocellular carcinoma patients. World J. Gastroenterol. 12(24), 3911–3914 (2006)

    PubMed  CAS  Google Scholar 

  26. O. Gautschi, C. Bigosch, B. Huegli, M. Jermann, A. Marx, E. Chassé, D. Ratschiller, W. Weder, M. Joerger, D.C. Betticher, R.A. Stahel, A. Ziegler, Circulating deoxyribonucleic Acid as prognostic marker in non-small-cell lung cancer patients undergoing chemotherapy. J. Clin. Oncol. 22(20), 4157–4164 (2004)

    PubMed  CAS  Google Scholar 

  27. A.A. Kamat, M. Baldwin, D. Urbauer, D. Dang, L.Y. Han, A. Godwin, B.Y. Karlan, J.L. Simpson, D.M. Gershenson, R.L. Coleman, F.Z. Bischoff, A.K. Sood, Plasma cell-free DNA in ovarian cancer: an independent prognostic biomarker. Cancer 116(8), 1918–1925 (2010)

    PubMed  CAS  Google Scholar 

  28. Z.H. Huang, L.H. Li, D. Hua, Quantitative analysis of plasma circulating DNA at diagnosis and during follow-up of breast cancer patients. Cancer Lett. 243(1), 64–70 (2006)

    PubMed  CAS  Google Scholar 

  29. M. Frattini, G. Gallino, S. Signoroni, D. Balestra, L. Lusa, L. Battaglia, G. Sozzi, L. Bertario, E. Leo, S. Pilotti, M.A. Pierotti, Quantitative and qualitative characterization of plasma DNA identifies primary and recurrent colorectal cancer. Cancer Lett. 263(2), 170–181 (2008)

    PubMed  CAS  Google Scholar 

  30. F. Banki, R.J. Mason, D. Oh, J.A. Hagen, S.R. DeMeester, J.C. Lipham, K. Tanaka, K.D. Danenberg, W.N. Yacoub, P.V. Danenberg, T.R. DeMeester, Plasma DNA as a molecular marker for completeness of resection and recurrent disease in patients with esophageal cancer. Arch. Surg. 142(6), 533–538 (2007)

    PubMed  CAS  Google Scholar 

  31. R.A. Perego, M. Corizzato, P. Brambilla, S. Ferrero, C. Bianchi, E. Fasoli, S. Signorini, B. Torsello, L. Invernizzi, S. Bombelli, V. Angeloni, M. Pitto, C. Battaglia, V. Proserpio, F. Magni, G. Galasso, P. Mocarelli, Concentration and microsatellite status of plasma DNA for monitoring patients with renal carcinoma. Eur. J. Cancer 44(7), 1039–1047 (2008)

    PubMed  CAS  Google Scholar 

  32. G. Sozzi, D. Conte, L. Mariani, S. Lo Vullo, L. Roz, C. Lombardo, M.A. Pierotti, L. Tavecchio, Analysis of circulating tumor DNA in plasma at diagnosis and during follow-up of lung cancer patients. Cancer Res. 61(12), 4675–4678 (2001)

    PubMed  CAS  Google Scholar 

  33. B.G. Wang, H.Y. Huang, Y.C. Chen, R.E. Bristow, K. Kassauei, C.C. Cheng, R. Roden, L.J. Sokoll, D.W. Chan, S. IeM, Increased plasma DNA integrity in cancer patients. Cancer Res. 63(14), 3966–3968 (2003)

    PubMed  CAS  Google Scholar 

  34. N. Umetani, J. Kim, S. Hiramatsu, H.A. Reber, O.J. Hines, A.J. Bilchik, D.S. Hoon, Increased integrity of free circulating DNA in sera of patients with colorectal or periampullary cancer: direct quantitative PCR for ALU repeats. Clin. Chem. 52(6), 1062–1069 (2006)

    PubMed  CAS  Google Scholar 

  35. N. Umetani, A.E. Giuliano, S.H. Hiramatsu, F. Amersi, T. Nakagawa, S. Martino, D.S. Hoon, Prediction of breast tumor progression by integrity of free circulating DNA in serum. J. Clin. Oncol. 24(26), 4270–4276 (2006)

    PubMed  CAS  Google Scholar 

  36. R. Hanley, K.M. Rieger-Christ, D. Canes, N.R. Emara, A.P. Shuber, K.A. Boynton, J.A. Libertino, I.C. Summerhayes, DNA integrity assay: a plasma-based screening tool for the detection of prostate cancer. Clin. Cancer Res. 12(15), 4569–4574 (2006)

    PubMed  CAS  Google Scholar 

  37. H. Tomita, D. Ichikawa, D. Ikoma, S. Sai, N. Tani, H. Ikoma, H. Fujiwara, S. Kikuchi, K. Okamoto, T. Ochiai, E. Otsuji, Quantification of circulating plasma DNA fragments as tumor markers in patients with esophageal cancer. Anticancer Res. 27(4C), 2737–2741 (2007)

    PubMed  CAS  Google Scholar 

  38. W.W. Jiang, M. Zahurak, D. Goldenberg, Y. Milman, H.L. Park, W.H. Westra, W. Koch, D. Sidransky, J. Califano, Increased plasma DNA integrity index in head and neck cancer patients. Int. J. Cancer 119(11), 2673–2676 (2006)

    PubMed  CAS  Google Scholar 

  39. B. Schmidt, S. Weickmann, C. Witt, M. Fleischhacker, Integrity of cell-free plasma DNA in patients with lung cancer and nonmalignant lung disease. Ann. N. Y. Acad. Sci. 1137, 207–213 (2008)

    PubMed  CAS  Google Scholar 

  40. S. Holdenrieder, A. Burges, O. Reich, F.W. Spelsberg, P. Stieber, DNA integrity in plasma and serum of patients with malignant and benign diseases. Ann. N. Y. Acad. Sci. 1137, 162–170 (2008)

    PubMed  CAS  Google Scholar 

  41. E. Gormally, P. Vineis, G. Matullo, F. Veglia, E. Caboux, E. Le Roux, M. Peluso, S. Garte, S. Guarrera, A. Munnia, L. Airoldi, H. Autrup, C. Malaveille, A. Dunning, K. Overvad, A. Tjønneland, E. Lund, F. Clavel-Chapelon, H. Boeing, A. Trichopoulou, D. Palli, V. Krogh, R. Tumino, S. Panico, H.B. Bueno-de-Mesquita, P.H. Peeters, G. Pera, C. Martinez, M. Dorronsoro, A. Barricarte, C. Navarro, J.R. Quirós, G. Hallmans, N.E. Day, T.J. Key, R. Saracci, R. Kaaks, E. Riboli, P. Hainaut, TP53 and KRAS2 mutations in plasma DNA of healthy subjects and subsequent cancer occurrence: a prospective study. Cancer Res. 66(13), 6871–6876 (2006)

    PubMed  CAS  Google Scholar 

  42. Z.M. Shao, J. Wu, Z.Z. Shen, M. Nguyen, p53 mutation in plasma DNA and its prognostic value in breast cancer patients. Clin. Cancer Res. 7(8), 2222–2227 (2001)

    PubMed  CAS  Google Scholar 

  43. T. Ito, K. Kaneko, R. Makino, K. Konishi, T. Kurahashi, H. Ito, A. Katagiri, M. Kushima, M. Kusano, K. Mitamura, M. Imawari, Clinical significance in molecular detection of p53 mutation in serum of patients with colorectal carcinoma. Oncol. Rep. 10(6), 1937–1942 (2003)

    PubMed  CAS  Google Scholar 

  44. T. Kimura, W.S. Holland, T. Kawaguchi, S.K. Williamson, K. Chansky, J.J. Crowley, J.H. Doroshow, H.J. Lenz, D.R. Gandara, P.H. Gumerlock, Mutant DNA in plasma of lung cancer patients: potential for monitoring response to therapy. Ann. N. Y. Acad. Sci. 1022, 55–60 (2004)

    PubMed  CAS  Google Scholar 

  45. J. Däbritz, J. Hänfler, R. Preston, J. Stieler, H. Oettle, Detection of Ki-ras mutations in tissue and plasma samples of patients with pancreatic cancer using PNA-mediated PCR clamping and hybridisation probes. Br. J. Cancer 92(2), 405–412 (2005)

    PubMed  Google Scholar 

  46. R.E. Board, L. Knight, A. Greystoke, F.H. Blackhall, A. Hughes, C. Dive, M. Ranson, Biomark. Insights 2, 307–319 (2007)

    Google Scholar 

  47. G.S. Xie, A.R. Hou, L.Y. Li, Y.N. Gao, S.J. Cheng, Quantification of plasma DNA as a screening tool for lung cancer. Chin. Med. J. (Engl.) 117(10), 1485–1488 (2004)

    CAS  Google Scholar 

  48. L.J. Herrera, S. Raja, W.E. Gooding, T. El-Hefnawy, L. Kelly, J.D. Luketich, T.E. Godfrey, Quantitative analysis of circulating plasma DNA as a tumor marker in thoracic malignancies. Clin. Chem. 51(1), 113–118 (2005)

    PubMed  CAS  Google Scholar 

  49. V. Ludovini, L. Pistola, V. Gregorc, I. Floriani, E. Rulli, S. Piattoni, L. Di Carlo, A. Semeraro, S. Darwish, F.R. Tofanetti, L. Stocchi, Z. Mihaylova, G. Bellezza, R. Del Sordo, G. Daddi, L. Crinò, M. Tonato, Plasma DNA, microsatellite alterations, and p53 tumor mutations are associated with disease-free survival in radically resected non-small cell lung cancer patients: a study of the perugia multidisciplinary team for thoracic oncology. J. Thorac. Oncol. 3(4), 365–373 (2008)

    PubMed  Google Scholar 

  50. M. Paci, S. Maramotti, E. Bellesia, D. Formisano, L. Albertazzi, T. Ricchetti, G. Ferrari, V. Annessi, D. Lasagni, C. Carbonelli, S. De Franco, M. Brini, G. Sgarbi, R. Lodi, Circulating plasma DNA as diagnostic biomarker in non-small cell lung cancer. Lung Cancer 64(1), 92–97 (2009)

    PubMed  Google Scholar 

  51. K.A. Yoon, S. Park, S.H. Lee, J.H. Kim, J.S. Lee, Comparison of circulating plasma DNA levels between lung cancer patients and healthy controls. Mol. Diagn. 11(3), 182–185 (2009)

    CAS  Google Scholar 

  52. A. Szpechcinski, M. Dancewicz, P. Kopinski, J. Kowalewski, J. Chorostowska-Wynimko, Real-time PCR quantification of plasma DNA in non-small cell lung cancer patients and healthy controls. Eur. J. Med. Res. 14(Suppl 4), 237–240 (2009)

    PubMed  Google Scholar 

  53. S. Kumar, R. Guleria, V. Singh, A.C. Bharti, A. Mohan, B.C. Das, Efficacy of circulating plasma DNA as a diagnostic tool for advanced non-small cell lung cancer and its predictive utility for survival and response to chemotherapy. Lung Cancer 70(2), 211–217 (2010)

    PubMed  Google Scholar 

  54. A. Szpechcinski, J. Chorostowska-Wynimko, W. Kupis, K. Maszkowska-Kopij, M. Dancewicz, J. Kowalewski, T. Orlowski, Quantitative analysis of free-circulating DNA in plasma of patients with resectable NSCLC. Expert Opin. Biol. 12(Suppl 1), S3–S9 (2012)

    CAS  Google Scholar 

  55. R. Catarino, A. Coelho, A. Araújo, M. Gomes, A. Nogueira, C. Lopes, R. Medeiros, Circulating DNA: diagnostic tool and predictive marker for overall survival of NSCLC patients. PLoS One 7(6), e38559 (2012)

    PubMed  CAS  Google Scholar 

  56. P. Ulivi, L. Mercatali, G.L. Casoni, E. Scarpi, L. Bucchi, R. Silvestrini, S. Sanna, M. Monteverde, D. Amadori, V. Poletti, W. Zoli, Multiple marker detection in peripheral blood for NSCLC diagnosis. PLoS One 8(2), e57401 (2013)

    PubMed  CAS  Google Scholar 

  57. R. Zhang, F. Shao, X. Wu, K. Ying, Value of quantitative analysis of circulating cell free DNA as a screening tool for lung cancer: a meta-analysis. Lung Cancer 69(2), 225–231 (2010)

    PubMed  Google Scholar 

  58. R. Rami-Porta, D. Ball, J. Crowley, D.J. Giroux, J. Jett, W.D. Travis, M. Tsuboi, E. Vallières, P. Goldstraw, International Staging Committee; Cancer Research and Biostatistics; Observers to the Committee; Participating Institutions, The IASLC Lung Cancer Staging Project: proposals for the revision of the T descriptors in the forthcoming (seventh) edition of the TNM classification for lung cancer. J. Thorac. Oncol. 2(7), 593–602 (2007)

    PubMed  Google Scholar 

  59. Y. Saito, N. Nagamoto, S. Ota, M. Sato, M. Sagawa, K. Kamma, S. Takahashi, K. Usuda, C. Endo, T. Imai, Results of surgical treatment for roentgenographically occult bronchogenic squamous cell carcinoma. J. Thorac. Cardiovasc. Surg. 104(2), 401–407 (1992)

    PubMed  CAS  Google Scholar 

  60. G. Sozzi, L. Roz, D. Conte, L. Mariani, F. Andriani, S. Lo Vullo, C. Verri, U. Pastorino, Plasma DNA quantification in lung cancer computed tomography screening: five-year results of a prospective study. Am. J. Respir. Crit. Care Med. 179(1), 69–74 (2009)

    PubMed  Google Scholar 

  61. G.L. Casoni, P. Ulivi, L. Mercatali, M. Chilosi, S. Tomassetti, M. Romagnoli, C. Ravaglia, C. Gurioli, C. Gurioli, W. Zoli, R. Silvestrini, V. Poletti, Increased levels of free circulating DNA in patients with idiopathic pulmonary fibrosis. Int. J. Biol. Markers 25(4), 229–235 (2010)

    PubMed  CAS  Google Scholar 

  62. R. Sirera, R.M. Bremnes, A. Cabrera, E. Jantus-Lewintre, E. Sanmartìn, A. Blasco, N. del Pozo, R. Rosell, R. Guijarro, J. Galbis, J.J. Sànchez, C. Camps, Circulating DNA is a useful prognostic factor in patients with advanced non-small cell lung cancer. J. Thorac. Oncol. 6(2), 286–290 (2011)

    PubMed  Google Scholar 

  63. M.A. van der Drift, B.E. Hol, C.H. Klaassen, C.F. Prinsen, Y.A. van Aarssen, R. Donders, J.W. van der Stappen, P.N. Dekhuijzen, H.F. van der Heijden, F.B. Thunnissen, Circulating DNA is a non-invasive prognostic factor for survival in non-small cell lung cancer. Lung Cancer 68(2), 283–287 (2010)

    PubMed  Google Scholar 

  64. A.K. Pathak, M. Bhutani, S. Kumar, A. Mohan, R. Guleria, Circulating cell-free DNA in plasma/serum of lung cancer patients as a potential screening and prognostic tool. Clin. Chem. 52(10), 1833–1842 (2006)

    PubMed  CAS  Google Scholar 

  65. M. Beau-Faller, M.P. Gaub, A. Schneider, X. Ducrocq, G. Massard, B. Gasser, M.P. Chenard, R. Kessler, P. Anker, M. Strounm, E. Weitzenblum, G. Pauli, J.M. Wihlm, E. Quoix, P. Oudet, Plasma DNA microsatellite panel as sensitive and tumor-specific marker in lung cancer patients. Int. J. Cancer 105(3), 361–370 (2003)

    PubMed  CAS  Google Scholar 

  66. Y.J. Lee, K.A. Yoon, J.Y. Han, H.T. Kim, T. Yun, G.K. Lee, H.Y. Kim, J.S. Lee, Circulating cell-free DNA in plasma of never smokers with advanced lung adenocarcinoma receiving gefitinib or standard chemotherapy as first-line therapy. Clin. Cancer Res. 17(15), 5179–5187 (2011)

    PubMed  CAS  Google Scholar 

  67. M. Esteller, M. Sanchez-Cespedes, R. Rosell, D. Sidransky, S.B. Baylin, J.G. Herman, Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res. 59(1), 67–70 (1999)

    PubMed  CAS  Google Scholar 

  68. A. Bearzatto, D. Conte, M. Frattini, N. Zaffaroni, F. Andriani, D. Balestra, L. Tavecchio, M.G. Daidone, G. Sozzi, p16(INK4A) Hypermethylation detected by fluorescent methylation-specific PCR in plasmas from non-small cell lung cancer. Clin. Cancer Res. 8(12), 3782–3787 (2002)

    PubMed  CAS  Google Scholar 

  69. Y. Liu, Q. An, L. Li, D. Zhang, J. Huang, X. Feng, S. Cheng, Y. Gao, Hypermethylation of p16INK4a in Chinese lung cancer patients: biological and clinical implications. Carcinogenesis 24(12), 1897–1901 (2003)

    PubMed  CAS  Google Scholar 

  70. P. Ulivi, W. Zoli, D. Calistri, F. Fabbri, A. Tesei, M. Rosetti, M. Mengozzi, D. Amadori, p16INK4A and CDH13 hypermethylation in tumor and serum of non-small cell lung cancer patients. J. Cell. Physiol. 206(3), 611–615 (2006)

    PubMed  CAS  Google Scholar 

  71. K. Fujiwara, N. Fujimoto, M. Tabata, K. Nishii, K. Matsuo, K. Hotta, T. Kozuki, M. Aoe, K. Kiura, H. Ueoka, M. Tanimoto, Identification of epigenetic aberrant promoter methylation in serum DNA is useful for early detection of lung cancer. Clin. Cancer Res. 11(3), 1219–1225 (2005)

    PubMed  CAS  Google Scholar 

  72. H.S. Hsu, T.P. Chen, C.H. Hung, C.K. Wen, R.K. Lin, H.C. Lee, Y.C. Wang, Characterization of a multiple epigenetic marker panel for lung cancer detection and risk assessment in plasma. Cancer 110(9), 2019–2026 (2007)

    PubMed  CAS  Google Scholar 

  73. K.L. Ostrow, M.O. Hoque, M. Loyo, M. Brait, A. Greenberg, J.M. Siegfried, J.R. Grandis, A. Gaither Davis, W.L. Bigbee, W. Rom, D. Sidransky, Molecular analysis of plasma DNA for the early detection of lung cancer by quantitative methylation-specific PCR. Clin. Cancer Res. 16(13), 3463–3472 (2010)

    PubMed  CAS  Google Scholar 

  74. Y. Zhang, R. Wang, H. Song, G. Huang, J. Yi, Y. Zheng, J. Wang, L. Chen, Methylation of multiple genes as a candidate biomarker in non-small cell lung cancer. Cancer Lett. 303(1), 21–28 (2011)

    PubMed  CAS  Google Scholar 

  75. S. Begum, M. Brait, S. Dasgupta, K.L. Ostrow, M. Zahurak, A.L. Carvalho, J.A. Califano, S.N. Goodman, W.H. Westra, M.O. Hoque, D. Sidransky, An epigenetic marker panel for detection of lung cancer using cell-free serum DNA. Clin. Cancer Res. 17(13), 4494–4503 (2011)

    PubMed  CAS  Google Scholar 

  76. K. Woodson, J. Mason, S.W. Choi, T. Hartman, J. Tangrea, J. Virtamo, P.R. Taylor, D. Albanes, Hypomethylation of p53 in peripheral blood DNA is associated with the development of lung cancer. Cancer Epidemiol. Biomarkers Prev. 10(1), 69–74 (2001)

    PubMed  CAS  Google Scholar 

  77. T.S. Mok, Y.L. Wu, S. Thongprasert, C.H. Yang, D.T. Chu, N. Saijo, P. Sunpaweravong, B. Han, B. Margono, Y. Ichinose, Y. Nishiwaki, Y. Ohe, J.J. Yang, B. Chewaskulyong, H. Jiang, E.L. Duffield, C.L. Watkins, A.A. Armour, M. Fukuoka, Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 361(10), 947–957 (2009)

    PubMed  CAS  Google Scholar 

  78. R. Rosell, E. Carcereny, R. Gervais, A. Vergnenegre, B. Massuti, E. Felip, R. Palmero, R. Garcia-Gomez, C. Pallares, J.M. Sanchez, R. Porta, M. Cobo, P. Garrido, F. Longo, T. Moran, A. Insa, F. De Marinis, R. Corre, I. Bover, A. Illiano, E. Dansin, J. de Castro, M. Milella, N. Reguart, G. Altavilla, U. Jimenez, M. Provencio, M.A. Moreno, J. Terrasa, J. Muñoz-Langa, J. Valdivia, D. Isla, M. Domine, O. Molinier, J. Mazieres, N. Baize, R. Garcia-Campelo, G. Robinet, D. Rodriguez-Abreu, G. Lopez-Vivanco, V. Gebbia, L. Ferrera-Delgado, P. Bombaron, R. Bernabe, A. Bearz, A. Artal, E. Cortesi, C. Rolfo, M. Sanchez-Ronco, A. Drozdowskyj, C. Queralt, I. de Aguirre, J.L. Ramirez, J.J. Sanchez, M.A. Molina, M. Taron, L. Paz-Ares, Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie, Associazione Italiana Oncologia Toracica, Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 13(13), 239–246 (2012)

    PubMed  CAS  Google Scholar 

  79. P. Ulivi, W. Zoli, E. Chiadini, L. Capelli, P. Candoli, D. Calistri, R. Silvestrini, M. Puccetti, EGFR and K-ras mutations in cytologic samples from fine-needle aspirates in NSCLC patients. Eur. Respir. J. 40(1), 267–269 (2012)

    PubMed  CAS  Google Scholar 

  80. J.H. Smouse, E.S. Cibas, P.A. Jänne, V.A. Joshi, K.H. Zou, N.I. Lindeman, EGFR mutations are detected comparably in cytologic and surgical pathology specimens of nonsmall cell lung cancer. Cancer 117(1), 67–72 (2009)

    PubMed  Google Scholar 

  81. S. Savic, C. Tapia, B. Grilli, A. Rufle, M.P. Bihl, A. de Vito Barascud, M. Herzog, L. Terracciano, F. Baty, L. Bubendorf, Comprehensive epidermal growth factor receptor gene analysis from cytological specimens of non-small-cell lung cancers. Br. J. Cancer 98(1), 154–160 (2008)

    PubMed  CAS  Google Scholar 

  82. S. Maheswaran, L.V. Sequist, S. Nagrath, L. Ulkus, B. Brannigan, C.V. Collura, E. Inserra, S. Diederichs, A.J. Iafrate, D.W. Bell, S. Digumarthy, A. Muzikansky, D. Irimia, J. Settleman, R.G. Tompkins, T.J. Lynch, M. Toner, D.A. Haber, Detection of mutations in EGFR in circulating lung-cancer cells. N. Engl. J. Med. 359(4), 366–377 (2008)

    PubMed  CAS  Google Scholar 

  83. H. Kimura, M. Suminoe, K. Kasahara, T. Sone, T. Araya, S. Tamori, F. Koizumi, K. Nishio, K. Miyamoto, M. Fujimura, S. Nakao, Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA). Br. J. Cancer 97(6), 778–784 (2007)

    PubMed  CAS  Google Scholar 

  84. T.K. Yung, K.C. Chan, T.S. Mok, J. Tong, K.F. To, Y.M. Lo, Single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non-small cell lung cancer patients. Clin. Cancer Res. 15(6), 2076–2084 (2009)

    PubMed  CAS  Google Scholar 

  85. Y. Kuang, A. Rogers, B.Y. Yeap, L. Wang, M. Makrigiorgos, K. Vetrand, S. Thiede, R.J. Distel, P.A. Jänne, Noninvasive detection of EGFR T790M in gefitinib or erlotinib resistant non-small cell lung cancer. Clin. Cancer Res. 15(8), 2630–2636 (2009)

    PubMed  CAS  Google Scholar 

  86. C. He, M. Liu, C. Zhou, J. Zhang, M. Ouyang, N. Zhong, J. Xu, Detection of epidermal growth factor receptor mutations in plasma by mutant-enriched PCR assay for prediction of the response to gefitinib in patients with non-small-cell lung cancer. Int. J. Cancer 125(10), 2393–2399 (2009)

    PubMed  CAS  Google Scholar 

  87. H. Bai, L. Mao, H.S. Wang, J. Zhao, L. Yang, T.T. An, X. Wang, C.J. Duan, N.M. Wu, Z.Q. Guo, Y.X. Liu, H.N. Liu, Y.Y. Wang, J. Wang, Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer. J. Clin. Oncol. 27(16), 2653–2659 (2009)

    PubMed  CAS  Google Scholar 

  88. P.C. Mack, W.S. Holland, R.A. Burich, R. Sangha, L.J. Solis, Y. Li, L.A. Beckett, P.N. Jr Lara, A.M. Davies, D.R. Gandara, EGFR mutations detected in plasma are associated with patient outcomes in erlotinib plus docetaxel-treated non-small cell lung cancer. J. Thorac. Oncol. 4(12), 1466–1472 (2009)

    PubMed  Google Scholar 

  89. B. Jiang, F. Liu, L. Yang, W. Zhang, H. Yuan, J. Wang, G. Huang, Serum detection of epidermal growth factor receptor gene mutations using mutant-enriched sequencing in Chinese patients with advanced non-small cell lung cancer. J. Int. Med. Res. 39(4), 1392–1401 (2011)

    PubMed  CAS  Google Scholar 

  90. M. Brevet, M.L. Johnson, C.G. Azzoli, M. Ladanyi, Detection of EGFR mutations in plasma DNA from lung cancer patients by mass spectrometry genotyping is predictive of tumor EGFR status and response to EGFR inhibitors. Lung Cancer 73(1), 96–102 (2011)

    PubMed  Google Scholar 

  91. K. Taniguchi, J. Uchida, K. Nishino, T. Kumagai, T. Okuyama, J. Okami, M. Higashiyama, K. Kodama, F. Imamura, K. Kato, Quantitative detection of EGFR mutations in circulating tumor DNA derived from lung adenocarcinomas. Clin. Cancer Res. 17(24), 7808–7815 (2011)

    PubMed  CAS  Google Scholar 

  92. Y.M. Chen, W.C. Fan, P.C. Tseng, C.M. Tsai, T.Y. Chou, C.H. Wu, K.T. Chou, Y.C. Lee, R.P. Perng, J. Whang-Peng, Plasma epidermal growth factor receptor mutation analysis and possible clinical applications in pulmonary adenocarcinoma patients treated with erlotinib. Oncol. Lett. 3(3), 713–717 (2012)

    PubMed  CAS  Google Scholar 

  93. T. Nakamura, N. Sueoka-Aragane, K. Iwanaga, A. Sato, K. Komiya, N. Kobayashi, S. Hayashi, T. Hosomi, M. Hirai, E. Sueoka, S. Kimura, Application of a highly sensitive detection system for epidermal growth factor receptor mutations in plasma DNA. J. Thorac. Oncol. 7(9), 1369–1381 (2012)

    PubMed  CAS  Google Scholar 

  94. K. Goto, Y. Ichinose, Y. Ohe, N. Yamamoto, S. Negoro, K. Nishio, Y. Itoh, H. Jiang, E. Duffield, R. McCormack, N. Saijo, T. Mok, M. Fukuoka, Epidermal growth factor receptor mutation status in circulating free DNA in serum: from IPASS, a phase III study of gefitinib or carboplatin/paclitaxel in non-small cell lung cancer. J. Thorac. Oncol. 7(1), 115–121 (2012)

    PubMed  CAS  Google Scholar 

  95. E.A. Punnoose, S. Atwal, W. Liu, R. Raja, B.M. Fine, B.G. Hughes, R.J. Hicks, G.M. Hampton, L.C. Amler, A. Pirzkall, M.R. Lackner, Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib. Clin. Cancer Res. 18(8), 2391–2401 (2012)

    PubMed  CAS  Google Scholar 

  96. X. Zhao, R.B. Han, J. Zhao, J. Wang, F. Yang, W. Zhong, L. Zhang, L.Y. Li, M.Z. Wang, Comparison of Epidermal growth factor receptor mutation statuses in tissue and plasma in stage I-IV Non-small cell lung cancer patients. Respiration 85(2), 119–125 (2013)

    PubMed  CAS  Google Scholar 

  97. S. Wang, T. An, J. Wang, J. Zhao, Z. Wang, M. Zhuo, H. Bai, L. Yang, Y. Zhang, X. Wang, J. Duan, Y. Wang, Q. Guo, M. Wu, Potential clinical significance of a plasma-based KRAS mutation analysis in patients with advanced non-small cell lung cancer. Clin. Cancer Res. 16(4), 1324–1330 (2010)

    PubMed  CAS  Google Scholar 

  98. F. Andriani, D. Conte, T. Mastrangelo, M. Leon, C. Ratcliffe, L. Roz, G. Pelosi, P. Goldstraw, G. Sozzi, U. Pastorino, Detecting lung cancer in plasma with the use of multiple genetic markers. Int. J. Cancer 108(1), 91–96 (2004)

    PubMed  CAS  Google Scholar 

  99. G. Sozzi, K. Musso, C. Ratcliffe, P. Goldstraw, M.A. Pierotti, U. Pastorino, Detection of microsatellite alterations in plasma DNA of non-small cell lung cancer patients: a prospect for early diagnosis. Clin. Cancer Res. 5(10), 2689–2692 (1999)

    PubMed  CAS  Google Scholar 

  100. N. Bruhn, T. Beinert, C. Oehm, B. Jandrig, I. Petersen, X.Q. Chen, K. Possinger, M. Fleischhacker, Detection of microsatellite alterations in the DNA isolated from tumor cells and from plasma DNA of patients with lung cancer. Ann. N. Y. Acad. Sci. 906, 72–82 (2000)

    PubMed  CAS  Google Scholar 

  101. M.A. Thijssen, D.W. Swinkels, T.J. Ruers, J.B. de Kok, Difference between free circulating plasma and serum DNA in patients with colorectal liver metastases. Anticancer Res. 22(1A), 421–425 (2002)

    PubMed  Google Scholar 

  102. Y.Y. Lui, K.W. Chik, R.W. Chiu, C.Y. Ho, C.W. Lam, Y.M. Lo, Predominant hematopoietic origin of cell-free DNA in plasma and serum after sex-mismatched bone marrow transplantation. Clin. Chem. 48(3), 421–427 (2002)

    PubMed  CAS  Google Scholar 

  103. M. Jung, S. Klotzek, M. Lewandowski, M. Fleischhacker, K. Jung, Changes in concentration of DNA in serum and plasma during storage of blood samples. Clin. Chem. 49(6 Pt 1), 1028–1029 (2003)

    PubMed  CAS  Google Scholar 

  104. T.H. Lee, L. Montalvo, V. Chrebtow, M.P. Busch, Quantitation of genomic DNA in plasma and serum samples: higher concentrations of genomic DNA found in serum than in plasma. Transfusion 41(2), 276–282 (2001)

    PubMed  CAS  Google Scholar 

  105. J. Jen, L. Wu, D. Sidransky, An overview on the isolation and analysis of circulating tumor DNA in plasma and serum. Ann. N. Y. Acad. Sci. 906, 8–12 (2000)

    PubMed  CAS  Google Scholar 

  106. Y.Y. Lui, K.W. Chik, Y.M. Lo, Does centrifugation cause the ex vivo release of DNA from blood cells? Clin. Chem. 48(11), 2074–2076 (2002)

    PubMed  CAS  Google Scholar 

  107. X. Xue, M.D. Teare, I. Holen, Y.M. Zhu, P.J. Woll, Optimizing the yield and utility of circulating cell-free DNA from plasma and serum. Clin. Chim. Acta 404(2), 100–104 (2009)

    PubMed  CAS  Google Scholar 

  108. G. Sozzi, L. Roz, D. Conte, L. Mariani, F. Andriani, P. Verderio, U. Pastorino, Effects of prolonged storage of whole plasma or isolated plasma DNA on the results of circulating DNA quantification assays. J. Natl. Cancer Inst. 97(24), 1848–1850 (2005)

    PubMed  CAS  Google Scholar 

  109. J.B. de Kok, J.C. Hendriks, W.W. van Solinge, H.L. Willems, E.J. Mensink, D.W. Swinkels, Use of real-time quantitative PCR to compare DNA isolation methods. Clin. Chem. 44(10), 2201–2204 (1998)

    PubMed  Google Scholar 

  110. C. Stemmer, M. Beau-Faller, E. Pencreac’h, E. Guerin, A. Schneider, D. Jaqmin, E. Quoix, M.P. Gaub, P. Oudet, Use of magnetic beads for plasma cell-free DNA extraction: toward automation of plasma DNA analysis for molecular diagnostics. Clin. Chem. 49(11), 1953–1955 (2003)

    PubMed  CAS  Google Scholar 

  111. B. Schmidt, S. Weickmann, C. Witt, M. Fleischhacker, Improved method for isolating cell-free DNA. Clin. Chem. 51(8), 1561–1563 (2005)

    PubMed  CAS  Google Scholar 

  112. C.J. Jorgez, D.D. Dang, J.L. Simpson, D.E. Lewis, F.Z. Bischoff, Quantity versus quality: optimal methods for cell-free DNA isolation from plasma of pregnant women. Genet. Med. 8(10), 615–619 (2006)

    PubMed  CAS  Google Scholar 

  113. S.A. Bustin, V. Benes, J.A. Garson, J. Hellemans, J. Huggett, M. Kubista, R. Mueller, T. Nolan, M.W. Pfaffl, G.L. Shipley, J. Vandesompele, C.T. Wittwer, The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin. Chem. 55(4), 611–622 (2009)

    PubMed  CAS  Google Scholar 

  114. J.G. Herman, J.R. Graff, S. Myöhänen, B.D. Nelkin, S.B. Baylin, Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc. Natl. Acad. Sci. U. S. A. 93(18), 9821–9826 (1996)

    PubMed  CAS  Google Scholar 

  115. C.A. Eads, K.D. Danenberg, K. Kawakami, L.B. Saltz, C. Blake, D. Shibata, P.V. Danenberg, P.W. Laird, MethyLight: a high-throughput assay to measure DNA methylation. Nucleic Acids Res. 28(8), E32 (2000)

    PubMed  CAS  Google Scholar 

  116. S.A. Qureshi, M.U. Bashir, A. Yaqinuddin, Utility of DNA methylation markers for diagnosing cancer. Int. J. Surg. 8(3), 194–198 (2010)

    PubMed  Google Scholar 

  117. T. Tanaka, Y. Nagai, H. Miyazawa, N. Koyama, S. Matsuoka, A. Sutani, A. Huqun, K. Udagawa, Y. Murayama, M. Nagata, Y. Shimizu, K. Ikebuchi, M. Kanazawa, K. Kobayashi, K. Hagiwara, Reliability of the peptide nucleic acid-locked nucleic acid polymerase chain reaction clamp-based test for epidermal growth factor receptor mutations integrated into the clinical practice for non-small cell lung cancers. Cancer Sci. 98(2), 246–252 (2007)

    PubMed  CAS  Google Scholar 

  118. H. Kimura, Y. Fujiwara, T. Sone, H. Kunitoh, T. Tamura, K. Kasahara, K. Nishio, High sensitivity detection of epidermal growth factor receptor mutations in the pleural effusion of non-small cell lung cancer patients. Cancer Sci. 97(7), 642–648 (2006)

    PubMed  CAS  Google Scholar 

  119. K.A. Heyries, C. Tropini, M. Vaninsberghe, C. Doolin, O.I. Petriv, A. Singhal, K. Leung, C.B. Hughesman, C.L. Hansen, Megapixel digital PCR. Nat. Methods 8(8), 649–651 (2011)

    PubMed  CAS  Google Scholar 

  120. A. Narayan, N.J. Carriero, S.N. Gettinger, J. Kluytenaar, K.R. Kozak, T.I. Yock, N.E. Muscato, P. Ugarelli, R.H. Decker, A.A. Patel, Ultrasensitive measurement of hotspot mutations in tumor DNA in blood using error-suppressed multiplexed deep sequencing. Cancer Res. 72(14), 3492–3498 (2012)

    PubMed  CAS  Google Scholar 

Download references

Acknowledgments

The authors would like to thank Ursula Elbling for editing the manuscript.

Conflict of interest

The authors have no conflicts of interest to declare.

Author information

Authors and Affiliations

  1. Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Via Maroncelli 40, 47014, Meldola, FC, Italy

    Paola Ulivi & Rosella Silvestrini

Authors
  1. Paola Ulivi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rosella Silvestrini
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Paola Ulivi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ulivi, P., Silvestrini, R. Role of quantitative and qualitative characteristics of free circulating DNA in the management of patients with non-small cell lung cancer. Cell Oncol. 36, 439–448 (2013). https://doi.org/10.1007/s13402-013-0155-3

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13402-013-0155-3

Keywords

Search

Navigation